WIP Warsaw IBD Point Profesor Kierkuś

The trial evaluates KAN-101 as a potential therapy for celiac disease. Researchers aim to improve the villus-height:crypt depth ratio after a short gluten challenge. The study seeks to demonstrate safety, tolerability and clinical benefit in participants.

• Gluten challenge attenuation
• Duodenal histology improvement
• Assessment of histological biomarkers

WIP Warsaw IBD Point Profesor Kierkuś conducts these investigations at its gastroenterology department, offering patients access to cutting‑edge research.

A novel rectal formulation of rifamycin SV is being tested to induce remission in patients with mild to moderate left‑sided ulcerative colitis. The design compares the investigational product with a matching placebo to confirm efficacy. The goal is to provide a targeted, locally acting treatment option for inflammatory bowel disease.

• Enema‑based drug delivery
• Placebo‑controlled efficacy evaluation
• Targeting left‑sided disease

The site’s focus on immune‑mediated gastrointestinal conditions positions it as a hub for innovative therapeutic development.